儿童脑膜瘤的总生存与无进展生存:系统评价与个体患者水平Meta分析
该系统评价纳入20项研究、1010例儿童脑膜瘤患者,按WHO分级、NF1/NF2状态、切除程度和辅助放疗分层重建生存数据。WHO 3级无进展生存短于1、2级,NF1/NF2相关肿瘤无进展生存短于散发者,全切除改善无进展生存与总生存,放疗在3级肿瘤中改善两项生存。
要点
- WHO 3级肿瘤无进展生存72.1个月,短于1级209.8个月和2级137.5个月(p<0.001)
- 全切除组无进展生存113.8个月 vs 40.1个月(p<0.001),总生存602.9个月 vs 173.8个月(p<0.001)
- 3级肿瘤放疗组无进展生存72.5个月 vs 23.8个月(p=0.009),总生存140.7个月 vs 63.0个月(p=0.002);2级肿瘤无差异(p=0.43)
核心结论
- 儿童脑膜瘤中全切除和辅助放疗对改善高级别肿瘤结局具有关键作用,作者强调亟需基于可靠纵向数据的儿童专用管理指南。
研究设计与样本
- 系统评价与个体患者水平Meta分析,纳入20项研究(2011-2023年)、1010例儿童脑膜瘤病例,采用个体患者数据提取法从Kaplan-Meier曲线重建纵向生存数据,按WHO分级、NF1/NF2状态、切除程度和辅助放疗分层评估无进展生存与总生存。
主要发现
- 儿童脑膜瘤男女比例接近(52.1% vs 47.9%);WHO 3级无进展生存72.1个月,短于1级209.8个月和2级137.5个月(p<0.001);1级与2级总生存无显著差异
- NF1相关无进展生存59.7个月、NF2相关138.4个月,均短于散发180.6个月(p=0.02)
- 全切除组无进展生存113.8个月 vs 40.1个月(p<0.001),总生存602.9个月 vs 173.8个月(p<0.001)
- 3级肿瘤放疗组无进展生存72.5个月 vs 23.8个月(p=0.009),总生存140.7个月 vs 63.0个月(p=0.002);2级肿瘤放疗无显著差异(p=0.43)
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric meningiomas (PMs) are rare central nervous system tumors, accounting for 1-5% of all meningiomas, and differ from adult meningiomas in clinical, histopathological, and molecular features. Current guidelines primarily focus on adults, leaving a gap in evidence-based management for PMs. This study presents the largest meta-analysis of longitudinal individual patient data (IPD) to date, addressing progression-free survival (PFS) and overall survival (OS) in pediatric patients. METHODS: Data from 20 studies (2011-2023), including 1010 pediatric meningioma cases, were analyzed to assess PFS and OS stratified by WHO grade, NF1/NF2 status, extent of resection (EOR), and adjuvant radiotherapy. Longitudinal survival data were reconstructed from Kaplan-Meier curves using IPD extraction methods. RESULTS: PMs affect males and females nearly equally (52.1% vs. 47.9%). WHO grade 3 tumors had significantly shorter PFS (72.1 months) compared to grades 1 (209.8 months) and 2 (137.5 months) (p < 0.001). No significant OS difference between WHO grades 1 and 2 PMs were observed. NF1- and NF2-associated tumors showed shorter PFS (59.7 and 138.4 months) than sporadic cases (180.6 months) (p = 0.02). GTR significantly improved PFS (113.8 vs. 40.1 months, p < 0.001) and OS (602.9 vs. 173.8 months, p < 0.001). Radiotherapy enhanced PFS (72.5 vs. 23.8 months, p = 0.009) and OS (140.7 vs. 63.0 months, p = 0.002) in grade 3 tumors but not in WHO grade 2 PMs (p = 0.43). CONCLUSIONS: This largest meta-analysis highlights the critical roles of GTR and adjuvant radiotherapy in improving outcomes for high-grade PMs and underscores the urgent need for pediatric-specific management guidelines based on robust longitudinal data.
引用
- Wach J, Vychopen M, Basaran AE, et al. Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis. J Neurooncol. 2025. PMID: 39779595. doi:10.1007/s11060-024-04917-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。